Nicholas J. Vogelzang, MD

Articles

Updates in Genitourinary, Gynecologic Cancers From ASCO 2021: Drs Nick Vogelzang and Erin Crane

June 7th 2021

OncLive sits down with Nicholas J. Vogelzang, MD, and Erin K. Crane, MD, MPH to discuss the biggest abstracts in genitourinary cancers and gynecologic cancers, respectively, at the 2021 ASCO Annual Meeting.

Dr. Vogelzang Discusses PROSPECT Trial for Prostate Cancer

July 20th 2018

Nicholas J. Vogelzang, MD, site research leader for Comprehensive Cancer Centers of Nevada, member of US Oncology Network, 2018 Giant of Cancer Care

Dr. Vogelzang Discusses the Addition of Chemotherapy to ADT in Men With Prostate Cancer

June 9th 2014

Nicholas J. Vogelzang, MD,discusses results from the phase III CHAARTED (E3805) study that examined the addition of chemotherapy to androgen deprivation therapy (ADT) for the treatment of men with newly diagnosed metastatic, hormone-sensitive prostate cancer.

Radium-223 Dichloride: A Novel Treatment for CRPC and Symptomatic Bone Metastases

May 29th 2014

The recent approval of several new agents for the treatment of prostate cancer has heralded a new era for managing this condition.

Dr. Vogelzang Discusses the Prostate Health Cocktail

September 5th 2013

Nicholas J. Vogelzang, MD, member of the US Oncology Network, site research leader for Comprehensive Cancer Centers of Nevada, professor of medicine at the University of Nevada School of Medicine, describes the Prostate Health Cocktail.

Dr. Vogelzang on Two Analyses of the ALSYMPCA Trial

July 10th 2013

Nicholas J. Vogelzang, MD, from the University of Nevada School of Medicine, describes two additional analyses of the phase III ALSYMPCA trial.

Dr. Vogelzang Discusses First-Line Axitinib in mRCC

May 6th 2013

Nicholas J. Vogelzang, MD, from the Comprehensive Cancer Centers of Nevada, discusses the comparison of axitinib to sorafenib as first-line therapy in patients with metastatic renal cell carcinoma.

Dr. Vogelzang on Sequencing Abiraterone and Enzalutamide

March 1st 2013

Nicholas J. Vogelzang, MD, from Comprehensive Cancer Centers of Nevada, discusses sequencing abiraterone acetate and enzalutamide in the treatment of men with metastatic castration-resistant prostate cancer.

Dr. Vogelzang Discusses Radium-223 in Prostate Cancer

February 16th 2013

Nicholas J. Vogelzang, MD, from the Comprehensive Cancer Centers of Nevada, discusses an updated analysis of the phase III ALSYMPCA trial that examined radium-223 dichloride in patients who have CRPC with bone metastases.

Dr. Vogelzang Discusses the Cabozantinib Trial Design

July 20th 2011

Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses the Cabozantinib Trial Design

Dr. Vogelzang Discusses Cabozantinib's Dose Size

June 29th 2011

Dr. NJ Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses Cabozantinib's Dose Size

Dr. Vogelzang Describes Cabozantinib's Side Effects

June 21st 2011

Dr. Nicholas Vogelzang from the Comprehensive Cancer Centers of Nevada Describes Cabozantinib's side effects

Dr. Vogelzang on Cabozantinib Clinical Trial Results

June 20th 2011

Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada on Cabozantinib Clinical Trial Results

Dr. Vogelzang on XL184's Effect on Bone Metastases

June 16th 2011

Dr. Vogelzang From the Comprehensive Cancer Centers of Nevada on XL184's Effect on Bone Metastases.

Dr. Vogelzang Discusses Cabozantinib Trial Design

June 9th 2011

Dr. Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses Cabozantinib Trial Design

Dr. Vogelzang on Mortalities in the Cabozantinib Trial

June 7th 2011

Dr. Vogelzang from the Comprehensive Cancer Centers of Nevada discusses mortalities in cabozantinib trial.